A transcriptional activity assay showed that Mithramycin A significantly decreased SP1 transcriptional activity in all TFE3-fusion RCC cell lines tested (Fig. 3G) and expression of the downstream target BIRC5 was dramatically reduced upon drug treatment (Fig. 3H). This evidence concerns the gene TFE3 and renal cell carcinoma.